respond to discussion post
Regarding the element, diagnosis, I believe that 23andMe does include this. For example, internal environment factors within this company include providing extensive genetic information which include health risks, inherited conditions, and ancestry, which appeals to health-conscious and research-minded consumers. In the article it also states that by 2013, 23andMe had tested nearly 450,000 consumers, particularly in a time of increased public awareness of genetic testing. Lastly 23andMe has secured significant investments from prominent backers like Google Ventures, Johnson & Johnson, and various venture capitalists, as well as grants from the National Institute of Health, providing financial stability and resources for growth. Some external environment factors are a significant percentage of Americans expressing interest in genetic testing and the desire to use genetic information for health management, therefore 23andMe is positioned to capitalize on this trend. Also, The company sees potential in working with government health systems to utilize its database for public health improvements and cost savings, which could provide substantial revenue streams and further legitimacy.
Regarding the element, guiding policy, I believe 23andMe does not include this. By creating a guiding policy, 23andMe can address competitive challenges, enhance its market position, and drive growth through innovation and strategic collaborations. Finding a comprehensive approach that aligns with the company's strengths and opportunities while understanding potential risks and weaknesses can help the company thrive.
Lastly regarding the element, coherent actions, I believe 23andMe does not include this. In order to achieve this 23andMe should take an approach to have the FDA approve their business. They should work with government health agencies and public health organizations to use genetic data for public health initiatives, such as disease prevention programs and targeted health interventions. Another idea is they can create programs that leverage genetic data to improve population health management and preventive care strategies. They also can advocate for the integration of genetic testing into public health policies and practices.